Literature DB >> 1721515

Administration of haptoglobin during cardiopulmonary bypass surgery.

K Tanaka1, Y Kanamori, T Sato, C Kondo, Y Katayama, I Yada, H Yuasa, M Kusagawa.   

Abstract

A study was undertaken to evaluate hemolysis and subsequent renal damage in 14 patients undergoing cardiopulmonary bypass (CPB) surgery. In all patients, free haptoglobin disappeared completely 30 to 90 minutes into CPB, while free hemoglobin (Hb) levels increased progressively. The NAG index and alpha 1M index also increased progressively, indicating renal tubular injury due to hemolysis (Study 1). An additional 20 patients were monitored intraoperatively for plasma free Hb levels by a newly developed colorimetric method using a haptoglobin coated strip. Free Hb levels during CPB exceeded 30 mg/dl in 14 patients, who were immediately given haptoglobin. This treatment eliminated plasma free Hb within 30 minutes, and effectively prevented hemoglobinuria. Haptoglobin treatment brought significant decreases in the NAG index and alpha 1M index, suggesting a protective effect on renal function (Study 2).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721515

Source DB:  PubMed          Journal:  ASAIO Trans        ISSN: 0889-7190


  18 in total

Review 1.  Pharmacologic strategies for combating the inflammatory response.

Authors:  Clive Landis
Journal:  J Extra Corpor Technol       Date:  2007-12

2.  Increased plasma catalytic iron in patients may mediate acute kidney injury and death following cardiac surgery.

Authors:  David E Leaf; Mohan Rajapurkar; Suhas S Lele; Banibrata Mukhopadhyay; James D Rawn; Gyorgy Frendl; Sushrut S Waikar
Journal:  Kidney Int       Date:  2015-01-07       Impact factor: 10.612

3.  Postoperative acute kidney injury is associated with hemoglobinemia and an enhanced oxidative stress response.

Authors:  Frederic T Billings; Stephen K Ball; L Jackson Roberts; Mias Pretorius
Journal:  Free Radic Biol Med       Date:  2011-02-18       Impact factor: 7.376

4.  Acetaminophen attenuates lipid peroxidation in children undergoing cardiopulmonary bypass.

Authors:  Scott A Simpson; Hayden Zaccagni; David P Bichell; Karla G Christian; Bret A Mettler; Brian S Donahue; L Jackson Roberts; Mias Pretorius
Journal:  Pediatr Crit Care Med       Date:  2014-07       Impact factor: 3.624

Review 5.  Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.

Authors:  Dominik J Schaer; Paul W Buehler; Abdu I Alayash; John D Belcher; Gregory M Vercellotti
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

6.  The potential of Angeli's salt to decrease nitric oxide scavenging by plasma hemoglobin.

Authors:  Xiaojun He; Ivan Azarov; Anne Jeffers; Tennille Presley; Jodi Richardson; S Bruce King; Mark T Gladwin; Daniel B Kim-Shapiro
Journal:  Free Radic Biol Med       Date:  2008-01-11       Impact factor: 7.376

Review 7.  Hemolysis in cardiac surgery patients undergoing cardiopulmonary bypass: a review in search of a treatment algorithm.

Authors:  Leen Vercaemst
Journal:  J Extra Corpor Technol       Date:  2008-12

Review 8.  Mechanisms of haemolysis-induced kidney injury.

Authors:  Kristof Van Avondt; Erfan Nur; Sacha Zeerleder
Journal:  Nat Rev Nephrol       Date:  2019-08-27       Impact factor: 28.314

9.  Haptoglobin improves shock, lung injury, and survival in canine pneumonia.

Authors:  Kenneth E Remy; Irene Cortés-Puch; Steven B Solomon; Junfeng Sun; Benjamin M Pockros; Jing Feng; Juan J Lertora; Roy R Hantgan; Xiaohua Liu; Andreas Perlegas; H Shaw Warren; Mark T Gladwin; Daniel B Kim-Shapiro; Harvey G Klein; Charles Natanson
Journal:  JCI Insight       Date:  2018-09-20

10.  Blood transfusions increase circulating plasma free hemoglobin levels and plasma nitric oxide consumption: a prospective observational pilot study.

Authors:  Iris C Vermeulen Windsant; Norbert C J de Wit; Jonas T C Sertorio; Erik A M Beckers; Jose E Tanus-Santos; Michael J Jacobs; Wim A Buurman
Journal:  Crit Care       Date:  2012-05-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.